Maha Abdelmonem Hegazy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maha Abdelmonem Hegazy has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Dalia Mohamed
Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, Ein Helwan, 11795 Cairo, Egypt; Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts, 11787 6 October City, Egypt
7 shared publications Hayam M. Lotfy
Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Science & Pharmaceutical Industries, Future University, Cairo, 12311, Egypt
6 shared publicationsM. Abdelkawy
Department of Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
6 shared publicationsShereen Mowaka
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, 11837, Egypt; Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, Ein Helwan, Cairo, Egypt
6 shared publications- Ahmed K. Kammoun
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80260, Jeddah 21589, Saudi Arabia
5 shared publications Ahmed S. Fayed
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr Al-Aini Street, 11562, Cairo, Egypt
4 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in BMC Chemistry
- Vol. 20 (1) , 192
Green chiral HPLC method on a polysaccharide column under hydro-organic conditions for the determination of Levobupivacaine, Ropivacaine, and their enantiomeric impurities
A novel, rapid, green, and enantioselective HPLC method was developed and validated using a polysaccharide-based chiral column for the individual determina
- 25 September 2026
- Published by Springer Nature in BMC Chemistry
- Vol. 20 (1) , 192
Open AccessGreen chiral HPLC method on a polysaccharide column under hydro-organic conditions for the determination of Levobupivacaine, Ropivacaine, and their enantiomeric impurities
A novel, rapid, green, and enantioselective HPLC method was developed and validated using a polysaccharide-based chiral column for the individual determina
- Open Access
- 1 November 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-16
A novel stability-indicating chromatographic quantification of the antiparkinsonian drug safinamide in its pharmaceutical formulation employing HPTLC densitometry and ion-pair HPLC–DAD
Parkinson's disease (PD) emerges as a notable health concern among the elderly population. Safinamide mesylate (SAF) is a novel and emerging add-on therapy in PD treatment. The stability of innovative drug formulations and the development of appropriate stability-indicating methods are of great importance to modern pharmaceutical analysis. The current work has established novel comprehensive stability-indicating chromatographic approaches, HPTLC coupled with densitometric quantification and HPLC–DAD, for the selective assay of SAF in pharmaceutical formulation along with its synthetic precursor impurity; 4-hydroxy benzaldehyde (4-HBD) in presence of its stress induced degradation products. The stability of SAF was investigated under different stress conditions. It was found that SAF is likely to undergo acid, base hydrolysis, and oxidative degradation. Using mass spectrometry and infrared spectroscopy, the structures of the forced degradation products were confirmed and elucidated. The dissolution behavior of Parkimedine® Tablets was also monitored in the FDA suitable medium. Multiple assessment tools were used to evaluate the environmental sustainability of the proposed methods and the reported one. The greenness tools included Complex-GAPI and AGREE metrics. In addition, the innovative concepts of "blueness" and "whiteness" evaluation were incorporated through the newly introduced BAGI and RGB12 algorithms, respectively.
- 1 November 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-16
Open AccessA novel stability-indicating chromatographic quantification of the antiparkinsonian drug safinamide in its pharmaceutical formulation employing HPTLC densitometry and ion-pair HPLC–DAD
Parkinson's disease (PD) emerges as a notable health concern among the elderly population. Safinamide mesylate (SAF) is a novel and emerging add-on therapy in PD treatment. The stability of innovative drug formulations and the development of appropriate stability-indicating methods are of great importance to modern pharmaceutical analysis. The current work has established novel comprehensive stability-indicating chromatographic approaches, HPTLC coupled with densitometric quantification and HPLC–DAD, for the selective assay of SAF in pharmaceutical formulation along with its synthetic precursor impurity; 4-hydroxy benzaldehyde (4-HBD) in presence of its stress induced degradation products. The stability of SAF was investigated under different stress conditions. It was found that SAF is likely to undergo acid, base hydrolysis, and oxidative degradation. Using mass spectrometry and infrared spectroscopy, the structures of the forced degradation products were confirmed and elucidated. The dissolution behavior of Parkimedine® Tablets was also monitored in the FDA suitable medium. Multiple assessment tools were used to evaluate the environmental sustainability of the proposed methods and the reported one. The greenness tools included Complex-GAPI and AGREE metrics. In addition, the innovative concepts of "blueness" and "whiteness" evaluation were incorporated through the newly introduced BAGI and RGB12 algorithms, respectively.
- Open Access
- 16 August 2024
- Published by Springer Nature in Journal of Fluorescence
- Vol. 35 (7) , 5059-5070
Eco-Friendly Synchronous Spectrofluorimetric Method for Simultaneous Determination of Remdesivir and Acetyl Salicylic Acid in Spiked Human Plasma
Remdesivir and acetyl salicylic acid are often co-administered medications in the treatment of COVID-19, specifically targeting the viral infection and thromboembolism associated with the condition. Hence, it is essential to establish a technique that enables the concurrent quantification of these pharmaceutical compounds in plasma while also keeping environmentally friendly methods. Accordingly, the aim of this work is to simultaneously determine remdesivir and acetyl salicylic acid through a bioanalytical validated synchronous spectrofluorimetric method with applying principles of green chemistry. Since, the two drugs showed severe overlap after excitation at 242.0 nm, 284.0 nm for remdesivir and acetyl salicylic acid, respectively. The overlap was effectively overcome by using synchronous mode with a wavelength difference (Δλ) of 160.0 nm for remdesivir and 100.0 nm for acetyl salicylic acid. Different parameters have been optimized such as Δλ, solvent, pH and surfactant. A linear calibration was obtained over the concentration range 0.01–4.00 µg/mL for remdesivir and 0.01–3.00 µg/mL for acetyl salicylic acid and the method was precise and accurate. The method was successfully used for the investigation of pharmaceutical formulation and the quantification of the maximum plasma concentration (Cmax) of the two drugs. The method has been evaluated as an excellent green analytical method based on three greenness assessment tools.
- 16 August 2024
- Published by Springer Nature in Journal of Fluorescence
- Vol. 35 (7) , 5059-5070
Open AccessEco-Friendly Synchronous Spectrofluorimetric Method for Simultaneous Determination of Remdesivir and Acetyl Salicylic Acid in Spiked Human Plasma
Remdesivir and acetyl salicylic acid are often co-administered medications in the treatment of COVID-19, specifically targeting the viral infection and thromboembolism associated with the condition. Hence, it is essential to establish a technique that enables the concurrent quantification of these pharmaceutical compounds in plasma while also keeping environmentally friendly methods. Accordingly, the aim of this work is to simultaneously determine remdesivir and acetyl salicylic acid through a bioanalytical validated synchronous spectrofluorimetric method with applying principles of green chemistry. Since, the two drugs showed severe overlap after excitation at 242.0 nm, 284.0 nm for remdesivir and acetyl salicylic acid, respectively. The overlap was effectively overcome by using synchronous mode with a wavelength difference (Δλ) of 160.0 nm for remdesivir and 100.0 nm for acetyl salicylic acid. Different parameters have been optimized such as Δλ, solvent, pH and surfactant. A linear calibration was obtained over the concentration range 0.01–4.00 µg/mL for remdesivir and 0.01–3.00 µg/mL for acetyl salicylic acid and the method was precise and accurate. The method was successfully used for the investigation of pharmaceutical formulation and the quantification of the maximum plasma concentration (Cmax) of the two drugs. The method has been evaluated as an excellent green analytical method based on three greenness assessment tools.
- 25 June 2024
- Published by Egyptian Knowledge Bank in Egyptian Journal of Chemistry
Development and Validation of Green Stability-Indicating RP-HPLC Method for Estimation of Ertapenem: Degradation Kinetics and Structural Mass Elucidation Using MS
Ertapenem is an antibiotic that is used in the treatment of several bacterial infections, and it was recently approved for the treatment of the COVID-19 virus. A simple validated stability-indicating reversed phase High Performance Liquid Chromatographic (RP-HPLC) method was developed for ertapenem estimation. The separation was done using Pronto SIL® C18 (300 × 4.6 mm, 5 μm) as the stationary phase, methanol, and acidified water as the mobile phase in gradient mode with a flow rate of 1 mL/min and a pH 4.0 adjusted by orthophosphoric acid. The method was validated according to ICH guidelines. The linearity ranges from 5.00-120.00 µg/mL with LOD 1.60 µg/mL and LOQ 4.85 µg/mL. Afterwards, the degradation behaviour of ertapenem was studied under various stress conditions, including acidic, basic, oxidative, thermal, and photolytic. The degradation study showed stability of ertapenem under thermal, photolytic degradation and severe degradation under acid, basic and oxidative conditions. The kinetics parameters were studied for acidic and basic degradation. The parameters showed that it follows a pseudo-first order reaction. Degradation products were structurally elucidated using mass spectrometry. The method has been evaluated as an excellent green analytical method based on eco-scale penalty points and the analytical greenness metric approach.
- 25 June 2024
- Published by Egyptian Knowledge Bank in Egyptian Journal of Chemistry
Development and Validation of Green Stability-Indicating RP-HPLC Method for Estimation of Ertapenem: Degradation Kinetics and Structural Mass Elucidation Using MS
Ertapenem is an antibiotic that is used in the treatment of several bacterial infections, and it was recently approved for the treatment of the COVID-19 virus. A simple validated stability-indicating reversed phase High Performance Liquid Chromatographic (RP-HPLC) method was developed for ertapenem estimation. The separation was done using Pronto SIL® C18 (300 × 4.6 mm, 5 μm) as the stationary phase, methanol, and acidified water as the mobile phase in gradient mode with a flow rate of 1 mL/min and a pH 4.0 adjusted by orthophosphoric acid. The method was validated according to ICH guidelines. The linearity ranges from 5.00-120.00 µg/mL with LOD 1.60 µg/mL and LOQ 4.85 µg/mL. Afterwards, the degradation behaviour of ertapenem was studied under various stress conditions, including acidic, basic, oxidative, thermal, and photolytic. The degradation study showed stability of ertapenem under thermal, photolytic degradation and severe degradation under acid, basic and oxidative conditions. The kinetics parameters were studied for acidic and basic degradation. The parameters showed that it follows a pseudo-first order reaction. Degradation products were structurally elucidated using mass spectrometry. The method has been evaluated as an excellent green analytical method based on eco-scale penalty points and the analytical greenness metric approach.
- Open Access
- 5 April 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-14
Therapeutic drug monitoring of six contraindicated/co-administered drugs by simple and green RP-HPLC-PDA; application to spiked human plasma
Therapeutic drug monitoring is an important clinical testing of the drugs to monitor their concentrations in plasma in order to guarantee their optimal impact, and to avoid any side effects resulting from drug-drug interactions. A green reversed-phase high-performance liquid chromatographic method using a photodiode array detector (RP-HPLC-PDA) was developed for the simultaneous determination of three carbapenem antibiotics (Imipenem, ertapenem, and meropenem) with the co-formulated drug (cilastatin) and contraindicated drugs (probenecid and warfarin) in spiked human plasma. The separation was achieved at 25 °C using a gradient elution of a mixture of mobile phase A: methanol and mobile phase B: phosphate buffer (pH 3.0). The photodiode array detector was adjusted at 220 nm. Bioanalytical method validation was carried out as per the FDA guidelines, and the method showed good linearity ranges for the six drugs that included their Cmax levels along with low limits of quantification. Based on the results, the method was found to be accurate and precise; with high % recovery and good % RSD, respectively. The method was successfully applied to spiked human plasma, signifying a good potential to be implemented in future TDM studies of these drugs when co-administered together.
- 5 April 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-14
Open AccessTherapeutic drug monitoring of six contraindicated/co-administered drugs by simple and green RP-HPLC-PDA; application to spiked human plasma
Therapeutic drug monitoring is an important clinical testing of the drugs to monitor their concentrations in plasma in order to guarantee their optimal impact, and to avoid any side effects resulting from drug-drug interactions. A green reversed-phase high-performance liquid chromatographic method using a photodiode array detector (RP-HPLC-PDA) was developed for the simultaneous determination of three carbapenem antibiotics (Imipenem, ertapenem, and meropenem) with the co-formulated drug (cilastatin) and contraindicated drugs (probenecid and warfarin) in spiked human plasma. The separation was achieved at 25 °C using a gradient elution of a mixture of mobile phase A: methanol and mobile phase B: phosphate buffer (pH 3.0). The photodiode array detector was adjusted at 220 nm. Bioanalytical method validation was carried out as per the FDA guidelines, and the method showed good linearity ranges for the six drugs that included their Cmax levels along with low limits of quantification. Based on the results, the method was found to be accurate and precise; with high % recovery and good % RSD, respectively. The method was successfully applied to spiked human plasma, signifying a good potential to be implemented in future TDM studies of these drugs when co-administered together.
- Open Access
- 30 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Stability-indicating UPLC assay coupled with mass spectrometry for the analysis of vilanterol degradation products in human urine
Vilanterol is a once-daily dose inhaler prescribed for asthma and chronic obstructive pulmonary disease. This study involved an investigation of vilanterol stability under acidic, basic, oxidative, thermal, and photolytic stress conditions. UPLC method was developed and validated for the analysis of vilanterol with its degradants. The drug was stable under photolytic and thermal stress conditions and degraded under acidic, basic, and oxidative stress conditions. Degradation kinetics was performed for acidic, basic and oxidative stress conditions. Kinetics parameters, K, half-life time (t1/2) and shelf-life time (t90) were assessed, and the degradation followed first order reaction. The method was linear from 0.10 to 100.00 µg mL−1 with accuracy, inter-day and intra-day precision from 99.45 to 100.02%, 0.391–0.694 and 0.041–0.345, respectively. Mass spectrometry was employed to elucidate the structure of the degradants, and the results revealed that certain degradation products were comparable to vilanterol metabolites. The World Anti-Doping Agency has prohibited the presence of vilanterol and its metabolites in athletes’ urine except for exercise bronchoconstriction with limited dose. So, quantification of vilanterol in the presence of its degradants was performed in human urine. The results revealed that the method was linear in range of 1.00 to 100.00 µg mL−1. Samples collection and experimental protocol was performed according to the guidelines of the Research Ethics Committee of the Faculty of Pharmacy, the British University in Egypt with approval No. CH-2305.
- 30 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Open AccessStability-indicating UPLC assay coupled with mass spectrometry for the analysis of vilanterol degradation products in human urine
Vilanterol is a once-daily dose inhaler prescribed for asthma and chronic obstructive pulmonary disease. This study involved an investigation of vilanterol stability under acidic, basic, oxidative, thermal, and photolytic stress conditions. UPLC method was developed and validated for the analysis of vilanterol with its degradants. The drug was stable under photolytic and thermal stress conditions and degraded under acidic, basic, and oxidative stress conditions. Degradation kinetics was performed for acidic, basic and oxidative stress conditions. Kinetics parameters, K, half-life time (t1/2) and shelf-life time (t90) were assessed, and the degradation followed first order reaction. The method was linear from 0.10 to 100.00 µg mL−1 with accuracy, inter-day and intra-day precision from 99.45 to 100.02%, 0.391–0.694 and 0.041–0.345, respectively. Mass spectrometry was employed to elucidate the structure of the degradants, and the results revealed that certain degradation products were comparable to vilanterol metabolites. The World Anti-Doping Agency has prohibited the presence of vilanterol and its metabolites in athletes’ urine except for exercise bronchoconstriction with limited dose. So, quantification of vilanterol in the presence of its degradants was performed in human urine. The results revealed that the method was linear in range of 1.00 to 100.00 µg mL−1. Samples collection and experimental protocol was performed according to the guidelines of the Research Ethics Committee of the Faculty of Pharmacy, the British University in Egypt with approval No. CH-2305.
- 25 December 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 248, 115971
Potentiometric detection of apomorphine in human plasma using a 3D printed sensor
- 25 December 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 248, 115971
Potentiometric detection of apomorphine in human plasma using a 3D printed sensor
- Open Access
- 5 October 2023
- Published by Springer Nature in BMC Chemistry
- Vol. 17 (1) , 1-11
Smart chemometrics-assisted spectrophotometric methods for efficient resolution and simultaneous determination of paracetamol, caffeine, drotaverine HCl along with three of their corresponding related impurities
Three novel, simple and accurate multivariate spectrophotometric assisted mathematical techniques were developed for determination of paracetamol, caffeine, drotaverine HCl and their related impurities. The used multivariate algorithms are principal component regression (PCR), partial least squares (PLS), and synergy intervals partial least squares (siPLS). Linearity of the suggested methods was found to be (1.00–14.60, 1.40–7.00, 1.40–3.80, 1.00–3.00, 1.50–3.50 and 2.50–4.50 µg/mL) for paracetamol, caffeine, drotaverine HCl, and their related impurities; p-aminophenol, theophylline and homoveratric acid, correspondingly. The presented methods were effectively implemented in the determination of the cited compounds in their laboratory prepared mixtures. Commercially available tablet preparation was also analyzed using the applied methods where no impurities were detected and without interference from tablet additives. Moreover, statistical analysis did not reveal any noticeable differences between the obtained results and those acquired from the reported method in terms of accuracy and precision. The developed multivariate algorithms were validated by means of internal and external validation sets. The obtained results showed the siPLS algorithm’s superiority to PCR and PLS according to the values of correlation coefficient values (r) and the lowest root mean square error of prediction (RMSEP). The combination of four subintervals [10, 12, 14, and 17] produced the highest efficiency model. Furthermore, these methods may be an applicable substitute to HPLC ones in quality control laboratories during rush of analyses where several samples have to be analyzed in a short time.
- 5 October 2023
- Published by Springer Nature in BMC Chemistry
- Vol. 17 (1) , 1-11
Open AccessSmart chemometrics-assisted spectrophotometric methods for efficient resolution and simultaneous determination of paracetamol, caffeine, drotaverine HCl along with three of their corresponding related impurities
Three novel, simple and accurate multivariate spectrophotometric assisted mathematical techniques were developed for determination of paracetamol, caffeine, drotaverine HCl and their related impurities. The used multivariate algorithms are principal component regression (PCR), partial least squares (PLS), and synergy intervals partial least squares (siPLS). Linearity of the suggested methods was found to be (1.00–14.60, 1.40–7.00, 1.40–3.80, 1.00–3.00, 1.50–3.50 and 2.50–4.50 µg/mL) for paracetamol, caffeine, drotaverine HCl, and their related impurities; p-aminophenol, theophylline and homoveratric acid, correspondingly. The presented methods were effectively implemented in the determination of the cited compounds in their laboratory prepared mixtures. Commercially available tablet preparation was also analyzed using the applied methods where no impurities were detected and without interference from tablet additives. Moreover, statistical analysis did not reveal any noticeable differences between the obtained results and those acquired from the reported method in terms of accuracy and precision. The developed multivariate algorithms were validated by means of internal and external validation sets. The obtained results showed the siPLS algorithm’s superiority to PCR and PLS according to the values of correlation coefficient values (r) and the lowest root mean square error of prediction (RMSEP). The combination of four subintervals [10, 12, 14, and 17] produced the highest efficiency model. Furthermore, these methods may be an applicable substitute to HPLC ones in quality control laboratories during rush of analyses where several samples have to be analyzed in a short time.
- 26 August 2023
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
Design of Experiment-Based Green UPLC-DAD Method for the Simultaneous Determination of Indacaterol, Glycopyrronium and Mometasone in their Combined Dosage Form and Spiked Human Plasma
Indacaterol, is an ultra-long-acting β2 agonist, glycopyrronium is a long-acting muscarinic-antagonist and mometasone is a synthetic corticosteroid. They were used recently in combination for the treatment of severe asthma symptoms and chronic obstructive pulmonary disease. In this work, it was the first time to develop a green and environment friendly ultra-performance liquid chromatographic method using design expert program for the analysis of the three drugs in their combined dosage form. Also, the method was bioanalytically validated for the analysis of the three drugs in spiked human plasma samples. The method was linear in range from 0.50 to 100.0 μg mL−1 for indacaterol and mometasone and from 1.0 to 150.0 μg mL−1 for glycopyrronium. It showed high accuracy where, the % recovery for indacaterol, glycopyrronium and mometasone in plasma were ranged from 94.27 to 97.86%, 96.43 to 98.75% and 96.86 to 98.43%, respectively. Also, it was precise where, the % relative standard deviation for the inter-day precision was ranged from 2.571 to 3.484%, 3.180 to 4.123% and 3.150 to 3.984% and the intra-day precision was ranged from 2.351 to 3.125%, 2.512 to 3.544% and 2.961 to 3.983% for indacaterol, glycopyrronium and mometasone, respectively. The limit of detection and the limit of quantification for indacaterol and mometasone were 0.03 and 0.10 μg mL−1 while for glycopyrronium, they were 0.16 and 0.50 μg mL−1. Analytical quality by design and green chemistry combined approach. Analytical quality by design using central composite design model for the optimization of the chromatographic conditions with the least number of runs. The first developed RP-UPLC green method for the simultaneous determination of indacterol, glycopyrronium and mometasone. The method was applied for their analysis in spiked plasma samples and combined dosage form. The method greenness was determined by analytical eco-scale.
- 26 August 2023
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
Design of Experiment-Based Green UPLC-DAD Method for the Simultaneous Determination of Indacaterol, Glycopyrronium and Mometasone in their Combined Dosage Form and Spiked Human Plasma
Indacaterol, is an ultra-long-acting β2 agonist, glycopyrronium is a long-acting muscarinic-antagonist and mometasone is a synthetic corticosteroid. They were used recently in combination for the treatment of severe asthma symptoms and chronic obstructive pulmonary disease. In this work, it was the first time to develop a green and environment friendly ultra-performance liquid chromatographic method using design expert program for the analysis of the three drugs in their combined dosage form. Also, the method was bioanalytically validated for the analysis of the three drugs in spiked human plasma samples. The method was linear in range from 0.50 to 100.0 μg mL−1 for indacaterol and mometasone and from 1.0 to 150.0 μg mL−1 for glycopyrronium. It showed high accuracy where, the % recovery for indacaterol, glycopyrronium and mometasone in plasma were ranged from 94.27 to 97.86%, 96.43 to 98.75% and 96.86 to 98.43%, respectively. Also, it was precise where, the % relative standard deviation for the inter-day precision was ranged from 2.571 to 3.484%, 3.180 to 4.123% and 3.150 to 3.984% and the intra-day precision was ranged from 2.351 to 3.125%, 2.512 to 3.544% and 2.961 to 3.983% for indacaterol, glycopyrronium and mometasone, respectively. The limit of detection and the limit of quantification for indacaterol and mometasone were 0.03 and 0.10 μg mL−1 while for glycopyrronium, they were 0.16 and 0.50 μg mL−1. Analytical quality by design and green chemistry combined approach. Analytical quality by design using central composite design model for the optimization of the chromatographic conditions with the least number of runs. The first developed RP-UPLC green method for the simultaneous determination of indacterol, glycopyrronium and mometasone. The method was applied for their analysis in spiked plasma samples and combined dosage form. The method greenness was determined by analytical eco-scale.